Loading...
COGT logo

Cogent Biosciences, Inc.NasdaqGS:COGT 株式レポート

時価総額 US$6.6b
株価
n/a
1Y313.8%
7D-0.1%
1D0.5%
ポートフォリオ価値
​
表示

Cogent Biosciences, Inc.

NasdaqGS:COGT 株式レポート

時価総額：US$6.6b

Cogent Biosciences（COGT）株式概要

臨床段階のバイオテクノロジー企業であるコージェント・バイオサイエンシズ社は、遺伝的に定義された疾患に対する精密治療法の開発に注力している。 詳細

COGT ファンダメンタル分析
スノーフレーク・スコア
評価0/6
将来の成長5/6
過去の実績0/6
財務の健全性5/6
配当金0/6

報酬

収益は年間65.02%増加すると予測されています

リスク分析

収益が 100 万ドル未満 ( $0 )

過去1年間で株主の希薄化は大幅に進んだ


COGT Community Fair Values

Create Narrative

See what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW497,212 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
497,212 investors already sharing narratives
View all narratives

Cogent Biosciences, Inc. 競合他社

価格と性能

株価の高値、安値、推移の概要Cogent Biosciences
過去の株価
現在の株価US$38.69
52週高値US$43.73
52週安値US$8.80
ベータ0.34
1ヶ月の変化24.73%
3ヶ月変化8.62%
1年変化313.80%
3年間の変化211.51%
5年間の変化468.14%
IPOからの変化304.71%

最新ニュース

分析記事 • Jun 18

Cogent Biosciences (COGT) Stock Can APEX Trial Progress Justify A 10.6x P B Ratio

Cogent Biosciences (COGT) stock is in focus after the company released updated APEX trial data for bezuclastinib in advanced systemic mastocytosis, along with preclinical results for JAK2 V617F inhibitor CGT1145 at the 2026 EHA Congress. See our latest analysis for Cogent Biosciences. The latest APEX and CGT1145 data arrive as Cogent Biosciences trades at US$33.67, with recent momentum reflected in a 7.3% 7 day share price return. The 1 year total shareholder return of about 4.7x highlights...
Seeking Alpha • Jun 14

Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage

Summary Cogent Biosciences is positioned to build a niche KIT-mutant franchise, leveraging bezuclastinib across three pivotal indications with strong clinical data. COGT holds $866.4 million in cash, supporting operations through 2028 and enabling launches in systemic mastocytosis and GIST, mitigating near-term financing risk. Bezuclastinib has demonstrated robust efficacy in nonadvanced and advanced systemic mastocytosis and second-line GIST, with three regulatory filings and positive pivotal trial results. Despite stretched valuation metrics, I see COGT as an attractive opportunity for investors willing to accept regulatory and launch risk, given its maturing clinical and commercial profile. Read the full article on Seeking Alpha

Recent updates

分析記事 • Jun 18

Cogent Biosciences (COGT) Stock Can APEX Trial Progress Justify A 10.6x P B Ratio

Cogent Biosciences (COGT) stock is in focus after the company released updated APEX trial data for bezuclastinib in advanced systemic mastocytosis, along with preclinical results for JAK2 V617F inhibitor CGT1145 at the 2026 EHA Congress. See our latest analysis for Cogent Biosciences. The latest APEX and CGT1145 data arrive as Cogent Biosciences trades at US$33.67, with recent momentum reflected in a 7.3% 7 day share price return. The 1 year total shareholder return of about 4.7x highlights...
Seeking Alpha • Jun 14

Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage

Summary Cogent Biosciences is positioned to build a niche KIT-mutant franchise, leveraging bezuclastinib across three pivotal indications with strong clinical data. COGT holds $866.4 million in cash, supporting operations through 2028 and enabling launches in systemic mastocytosis and GIST, mitigating near-term financing risk. Bezuclastinib has demonstrated robust efficacy in nonadvanced and advanced systemic mastocytosis and second-line GIST, with three regulatory filings and positive pivotal trial results. Despite stretched valuation metrics, I see COGT as an attractive opportunity for investors willing to accept regulatory and launch risk, given its maturing clinical and commercial profile. Read the full article on Seeking Alpha
Seeking Alpha • Jan 18

Cogent Biosciences: Buy The Pullback For Bezuclastinib's 2025 SM And GIST Data

Summary Bezuclastinib is COGT’s main value driver, currently undergoing 3 late-stage trials for SM and GIST. COGT’s SUMMIT Part 2 for nonAdvSM will give us decisive data in July 2025, which I consider its main catalyst this year. Bezuclastinib could target an aggregate TAM of up to $2.5 billion across NonAdvSM, AdvSM, and GIST, which dwarves its current market cap. The company also has a solid cash runway of about 1.9 years and should be sufficient until we see its main catalyst play out. This is why I think the recent 34% decline is actually a good speculative “Buy” opportunity for investors betting on Bezuclastinib’s 2025 upcoming data. Read the full article on Seeking Alpha
Seeking Alpha • Jun 23

Cogent Biosciences: Inflection Year Directly Ahead

Summary Today, we revisit clinical stage biotech firm Cogent Biosciences for the first time since 2022. The company is heading into the potential inflection year in 2025 and top line results from three late-stage trials should be out during the year. Cogent Biosciences is also well funded and enjoys solid support from the analyst community. An updated analysis follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Feb 14

Cogent Biosciences: Stock Soars On Cash Injection Ahead Of Major Data Catalyst

Summary Cogent Biosciences, Inc. has entered into a securities purchase agreement for a private investment in public equity financing, expected to raise approximately $225 million. The financing was led by Commodore Capital and a large investment management firm, with participation from several notable biotech investment firms. The funds will be used for research and development, activities related to bezuclastinib, the company's lead candidate. The hope is that bezuclastinib can secure approval to treat advanced and non-advanced systemic mastocytosis - a >$2bn potential market. There is a major data catalyst upcoming, when the company announces Phase 2 data from its SUMMIT study in non-advSM. Blueprint medicines Ayvakit is already approved in this indication, and bezuclastinib must show superiority to this drug. If it can, the share price may soar again. Read the full article on Seeking Alpha
Seeking Alpha • Sep 13

Cogent Biosciences: What's Ahead

Summary Today, we put Cogent Biosciences, Inc. in the spotlight for the first time in nearly two years. Cogent stock has roughly tripled since positive trial data came out in June, and the company has addressed its current funding needs. More upside ahead? An investment analysis follows in the paragraphs below. A story only matters, I suspect, to the extent that the people in the story change.”― Neil Gaiman We circle back on Cogent Biosciences, Inc. (NASDAQ:COGT) today for the first time since our last piece on this company in October of 2020. At the time, the company was called Unum Therapeutics. Through a merger with privately held Kiq Bio soon thereafter, the company was reborn as Cogent Biosciences. So, is this newly born biotech concern a butterfly or a moth in relation to prospects for investors? An analysis follows below. Seeking Alpha Company Overview: Cogent Biosciences Inc. is based just outside of Boston in Cambridge, MA. This clinical stage biotech concern is focused on developing precision therapies for genetically defined diseases. Its stock currently trades around $17.00 a share and sports an approximate market capitalization of $1.1 billion. The company lead drug candidate is bezuclastinib. The compound is designed to target exon 17 mutations found within the KIT receptor tyrosine kinase, including KIT D816V. When this mutation remains in a perpetual "on" state, it causes mast cells to accumulate in various internal organs including the bone marrow. This leads to an Orphan Disease called Systemic Mastocytosis. Other Exon 17 mutations have been found in other afflictions such as advanced Gastrointestinal Stromal Tumors, or GIST. Bezuclastinib is a highly selective and potent KIT inhibitor that eventually could lead to effective treatments for these indications. June Company Presentation Bezuclastinib is currently being evaluated in several studies. The company is currently enrolling patients in an ongoing two part Phase 2 trial called "Apex." This study is evaluating bezuclastinib to treat patients with Advanced Systemic Mastocytosis (AdvSM). This is a rare, very aggressive form of Systemic Mastocytosis. The average lifespan of someone with this rare affliction is 3.5 years. The company posted encouraging interim results from this study on June 10th, which helped ignite a big rally in the stock since then. June Company Presentation Cogent is also currently enrolling patients in a study called Summit. This is a randomized, double-blind, placebo-controlled Phase 2 clinical trial of bezuclastinib in patients with Nonadvanced Systemic Mastocytosis or NonAdvSM. This is a life-long illness with chronic symptoms that occurs in approximately 90% of the people that have Systemic Mastocytosis. June Company Presentation Finally, the company is evaluating bezuclastinib as a potential treatment for GIST. These tumors are categorized by uncontrolled cell growth in the tissues of the gastrointestinal tract. Approximately 80% of GIST patients’ tumors are the result of primary KIT mutations. Bezuclastinib has studied in an 18 person Phase 1/2 trial both as monotherapy as well as part of a combination therapy with sunitinib. Median progression free survival [PFS] reached 11 months with these patients, most of these which were heavily treated previously. Currently approved therapies currently inhibit a subset of these mutations, but most patients develop resistance due to additional secondary KIT mutations, including mutations in Exon 17. Bezuclastinib is designed to inhibit the primary mutation while sunitinib looks to inhibit additional mutations.
Seeking Alpha • Jun 26

Cogent Biosciences: APEX Data Was Interesting, But We Need More

Cogent has a single molecule in various trials. Recently, they produced some positive early data. We should be able to get a better grasp on the company in about a year.

株主還元

COGTUS BiotechsUS 市場
7D-0.1%4.1%1.6%
1Y313.8%41.1%18.6%

業界別リターン: COGT過去 1 年間で41.1 % の収益を上げたUS Biotechs業界を上回りました。

リターン対市場: COGT過去 1 年間で18.6 % の収益を上げたUS市場を上回りました。

価格変動

Is COGT's price volatile compared to industry and market?
COGT volatility
COGT Average Weekly Movement5.0%
Biotechs Industry Average Movement10.3%
Market Average Movement7.3%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.2%

安定した株価: COGT 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。

時間の経過による変動: COGTの 週次ボラティリティ は、過去 1 年間で18%から5%に減少しました。

会社概要

設立従業員CEO（最高経営責任者ウェブサイト
n/a258Andy Robbinswww.cogentbio.com

コージェント・バイオサイエンシズ社は臨床段階のバイオテクノロジー企業で、遺伝的に定義された疾患に対する精密治療の開発に注力している。同社の主要製品候補には、全身性肥満細胞症を引き起こすKIT D816V変異を含むKIT受容体チロシンキナーゼ内の変異や、進行した消化管間質腫瘍患者に見られるKITエクソン17の他の変異を標的とするよう設計された、フェーズ3試験中の選択的チロシンキナーゼ阻害剤であるbezuclastinib（CGT9486）が含まれる。CGT4859は可逆的かつ選択的な線維芽細胞増殖因子受容体2阻害剤で、進行性胆管がんなどのFGFR変異が証明された患者を対象に第1相試験を実施中。CGT4255は新規ErbB2変異プログラムであり、固形がんの全身性および中枢神経系に関与する適応症において、実用化可能で十分な治療を受けていない変異に焦点を当てている。また、Plexxikon Inc.とベズクラスチニブの研究・開発・商業化に関するライセンス契約を締結している。本社はマサチューセッツ州ウォルサム。

Cogent Biosciences, Inc. 基礎のまとめ

Cogent Biosciences の収益と売上を時価総額と比較するとどうか。
COGT 基礎統計学
時価総額US$6.61b
収益（TTM）-US$354.30m
売上高(TTM)n/a
0.0x
P/Sレシオ
-18.7x
PER（株価収益率

COGT は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
COGT 損益計算書（TTM）
収益US$0
売上原価US$0
売上総利益US$0
その他の費用US$354.30m
収益-US$354.30m

直近の収益報告

Mar 31, 2026

次回決算日

該当なし

一株当たり利益（EPS）-2.07
グロス・マージン0.00%
純利益率0.00%
有利子負債／自己資本比率36.7%

COGT の長期的なパフォーマンスは？

過去の実績と比較を見る

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/07/06 13:09
終値2026/07/02 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Cogent Biosciences, Inc. 12 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。21

アナリスト機関
Colleen KusyBaird
David LebowitzCitigroup Inc
Kelsey GoodwinGuggenheim Securities, LLC